This is a paid press release. Contact the press release distributor directly with any inquiries.

Groundbreaking Clinical Study Reveals Promising Evidence for VIVAZEN®’s Kratom Extracts

Business Wire

Fri, February 20, 2026 at 5:56 AM GMT+9 2 min read

Findings unveiled at the University of Florida Scientific Kratom Symposium highlight encouraging results for adult use of low-dose proprietary kratom extracts

PHOENIX, February 19, 2026–(BUSINESS WIRE)–VIVAZEN® proudly announces the results of a pioneering 28-day clinical study evaluating the safety and tolerability of its proprietary kratom extracts.

The findings, presented by Dr. Jenelle Patterson of Gowling WLG, at the University of Florida Fifth Scientific Kratom Symposium, reinforce VIVAZEN®’s dedication to advancing knowledge in botanical wellness through rigorous scientific research. The study assessed the effects of VIVAZEN®’s proprietary kratom extract on adult participants, demonstrating no severe adverse events throughout the 28-day trial period. This research marks a significant step in understanding the safety profile of kratom extracts at low doses.

“From our inception, VIVAZEN® has prioritized credible, science-backed results, utilizing natural botanical ingredients,” stated Bryan Derr, Chief Operating Officer for VIVAZEN®. “Our approach seamlessly blends innovation with responsibility, emphasizing transparency, quality testing, and science. We believe in empowering adults to make informed wellness choices, and we are committed to openly sharing research findings to further support the case for botanical wellness.”

Key Study Insights

This groundbreaking study is the first clinical evaluation of our kratom extracts, focusing on tolerability and safety signals over a 28-day period. Notably, the study reported:

Kratom extracts were well-tolerated for 4 weeks of consecutive daily use.

No observed severe adverse events.

No evidence of dependence or withdrawal.

“Policy should be informed by scientific evidence, not fear-based assumptions,” emphasized principal investigator Dr. Paula Brown, Director of Applied Research at the BC Institute of Technology and Adjunct Professor, Pharmacognosy Institute and Department of Pharmaceutical Sciences, Retzky College of Pharmacy, University of Illinois Chicago.

“Consumers rely on and, frankly, deserve transparency and robust safety standards to make informed decisions about their wellness. Our hope is that studies like this will help guide policy decisions that acknowledge the potential benefits of kratom while prioritizing consumer safety.”

This clinical study contributes to a growing body of medical and scientific research supporting the health & wellness benefits of kratom in adults. Notably, the U.S. Food and Drug Administration has initiated human trials on kratom, reflecting continued scientific interest in further understanding kratom’s safety and pharmacology.

Story Continues  

The VIVAZEN® Commitment

VIVAZEN® products are formulated with safety and quality in mind. Each product undergoes third-party testing to ensure purity, strength, and compliance with our rigorous quality and safety standards. With increasing concerns about unlawful and potentially harmful products in the market, VIVAZEN® is committed to providing transparency and educating consumers on the responsible use of botanicals.

About VIVAZEN

For over a decade, VIVAZEN® has delivered trusted, high-quality botanical supplements that provide people with functional wellness without compromise. Grounded in centuries of wellness practices and backed by modern innovation, VIVAZEN® products offer functional, feel-good alternatives for those who want to live — and feel — on their own terms. Join the millions who trust VIVAZEN® to Feel Great™ naturally. Visit us at www.vivazen.com.

View source version on businesswire.com:

Contacts

Press@vivazen.com

Terms and Privacy Policy

Privacy Dashboard

More Info